1-{[(2-bromoethyl)oxy]methyl}-4-methylbenzene | 103061-53-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-{[(2-bromoethyl)oxy]methyl}-4-methylbenzene
• 英文别名: 1-(2-bromo-ethoxymethyl)-4-methylbenzene；1-(2-bromoethoxymethyl)-4-methylbenzene
• CAS: 103061-53-6
• 化学式: C₁₀H₁₃BrO
• 分子量: 229.117
• InChiKey: MKBKMNKJWKLKIC-UHFFFAOYSA-N

物化性质

• 沸点：
  278.4±20.0 °C(Predicted)
• 密度：
  1.312±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  二苯基(奎宁环-4-基)甲醇 、 1-{[(2-bromoethyl)oxy]methyl}-4-methylbenzene 以 氯仿 、 乙腈 为溶剂， 反应 16.0h， 以72.7 mg的产率得到4-[hydroxy(diphenyl)methyl]-1-(2-{[(4-methylphenyl)methyl]oxy}ethyl)-1-azoniabicyclo[2.2.2]octane bromide
  参考文献：
  名称：

  Discovery of Novel 1-Azoniabicyclo[2.2.2]octane Muscarinic Acetylcholine Receptor Antagonists

  摘要：

  A novel 4-hydroxyl(diphenyl)methyl substituted quinuclidine series was discovered as a very promising class of muscarinic antagonists. The structure-activity relationships of the connectivity of the diphenyl moiety to the quinuclidine core and around the ring nitrogen side chain are described. Computational docking studies using an homology model of the M-3 receptor readily explained the observed structure-activity relationship of the various compounds. Compound 14o was identified as a very potent, slowly reversible M-3 antagonist with a very long in vivo duration of bronchoprotection.

  DOI：

  10.1021/jm801601v
• 作为产物：
  描述：

  2-((4-methylbenzyl)oxy)ethanol 在 N-溴代丁二酰亚胺(NBS) 、 PS-PPh3 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 1-{[(2-bromoethyl)oxy]methyl}-4-methylbenzene
  参考文献：
  名称：

  Discovery of Novel 1-Azoniabicyclo[2.2.2]octane Muscarinic Acetylcholine Receptor Antagonists

  摘要：

  A novel 4-hydroxyl(diphenyl)methyl substituted quinuclidine series was discovered as a very promising class of muscarinic antagonists. The structure-activity relationships of the connectivity of the diphenyl moiety to the quinuclidine core and around the ring nitrogen side chain are described. Computational docking studies using an homology model of the M-3 receptor readily explained the observed structure-activity relationship of the various compounds. Compound 14o was identified as a very potent, slowly reversible M-3 antagonist with a very long in vivo duration of bronchoprotection.

  DOI：

  10.1021/jm801601v

文献信息

• COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST
  申请人：Harry Finch

  公开号：US20110046191A1

  公开（公告）日：2011-02-24

  The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a β 2 -adrenoceptor agonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.

  该发明提供了一种药品、试剂盒或组合物，包括第一活性成分，该成分为选择的肌动蛋白受体拮抗剂，以及第二活性成分，该成分为β2-肾上腺素能受体激动剂，用于治疗慢性阻塞性肺疾病和哮喘等呼吸系统疾病。
• Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection
  作者：Chee Wei Ang、Brendon M. Lee、Colin J. Jackson、Yuehong Wang、Scott G. Franzblau、Amanda F. Francisco、John M. Kelly、Paul V. Bernhardt、Lendl Tan、Nicholas P. West、Melissa L. Sykes、Alexandra O. Hinton、Raghu Bolisetti、Vicky M. Avery、Matthew A. Cooper、Mark A.T. Blaskovich

  DOI：10.1021/acs.jmedchem.2c00972

  日期：2022.10.13
• [EN] OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES<br/>[FR] DÉRIVÉS D'OXAZOLE ET DE THIAZOLE ET LEURS UTILISATIONS
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2008096093A1

  公开（公告）日：2008-08-14

  [EN] A quaternary ammonium compound of formula (I) having M3 receptor antagonist activity; a composition comprising such a compound; the use of such a compound in therapy (such as asthma or COPD); and a method of treating a patient with such a compound.
  [FR] L'invention concerne un composé d'ammonium quaternaire de formule (I) ayant une activité antagoniste du récepteur M3; une composition comprenant ce composé; l'utilisation de ce composé en thérapie (telle que le traitement de l'asthme ou de COPD (maladie pulmonaire obstructive chroniquesdu cheval)); et une méthode visant à traiter un patient avec ce composé.
• [EN] COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST<br/>[FR] COMBINAISON D'UN ANTAGONISTE DU RÉCEPTEUR MUSCARINIQUE ET D'UN AGONISTE DE L'ADRÉNORÉCEPTEUR ß2
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2008096126A1

  公开（公告）日：2008-08-14

  [EN] The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a ß₂-adrenoceptor agonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.
  [FR] L'invention concerne un produit pharmaceutique, une trousse ou une composition comprenant une premier ingrédient actif qui est un antagoniste du récepteur muscarinique choisi et un second ingrédient actif qui est un agoniste de l'adrénocepteur ß₂, destinés au traitement de maladies respiratoires telles que la maladie pulmonaire obstructive chronique et l'asthme.
• [EN] COMBINATIONS WITH A MUSCARINIC RECEPTOR ANTAGONIST<br/>[FR] COMBINAISON INÉDITE
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2008096136A1

  公开（公告）日：2008-08-14

  [EN] The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is selected from a phosphodiesterase inhibitor, a modulator of chemokine receptor function, an inhibitor of kinase function, a protease inhibitor, a steroidal glucocorticoid receptor agonist, a non-steroidal glucocorticoid receptor agonist and a purinoceptor antagonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.
  [FR] La présente invention a trait à un produit, une trousse ou une composition pharmaceutique comprenant un premier principe actif, qui est un antagoniste d'un récepteur muscarinique sélectionné, et un second principe actif, qui est choisi parmi un inhibiteur de la phosphodiestérase, un modulateur de l'action du récepteur des chimiokines, un inhibiteur de l'activité kinase, un inhibiteur des protéases, un agoniste stéroïdien du récepteur des glucocorticoïdes, un agoniste non stéroïdien du récepteur des glucocorticoïdes et un antagoniste du purinocepteur, utilisable dans le cadre du traitement de maladies respiratoires comme la bronchopneumopathie chronique obstructive et l'asthme.